文献速递肿瘤 PET/CT放射性药物与辐射防护

[68Ga]Ga-Pentixafor PET/CT定量分析中SUV归一化方法与参考组织的选择

Selection of SUV normalization and reference tissue for quantitative [68Ga]Ga-Pentixafor PET/CT analysis.
PubMed 文献 · EJNMMI Res · 2026-01-04

该研究回顾性分析40例无恶性肿瘤患者的[68Ga]Ga-Pentixafor PET/CT,比较SUVbw与两种基于去脂体重的SUL(James法与Janmahasatian法)在血池、肝、脾、骨髓和肌肉中的体重依赖性、可重复性与变异性。结果显示SUL-James能降低体重相关波动,肝和血池变异度最低,脾个体间变异大,提示SUL-James联合肝或血池可作为稳健的定量参考。

要点

  • SUL-James较SUVbw降低肝、脾等组织的体重相关性波动
  • 肝和血池的SUVmean与SULmean-James变异度最低(CQV 9.4%–16.8%)
  • 脾的个体间变异较大(CQV 19.9%–22.2%),不宜作为常规参考组织

核心结论

  • SUL-James归一化联合肝或血池作为参考组织,可为[68Ga]Ga-Pentixafor PET/CT提供稳健且可重复的定量。

研究设计与样本

  • 回顾性分析40例无恶性肿瘤患者的[68Ga]Ga-Pentixafor PET/CT扫描。
  • 在血池、肝、脾、骨髓和肌肉放置感兴趣区,计算SUVbw及基于James公式和Janmahasatian公式的SUL。
  • 用Spearman相关系数与线性回归斜率/截距比(a/b)评估体重相关性,用ICC和CQV评估观察者间可重复性与变异性。

主要发现

  • 除肌肉外,SUVmean、SULmean-James和SULmean-Janma在所有候选组织均显示显著体重依赖,以肝右叶相关性最强(ρ分别为0.635、0.576和0.650)。
  • 与SUVbw相比,James公式SUL降低体重相关波动:a/b在肝右叶由0.065降至0.034,肝左叶由0.036降至0.021,脾由0.076降至0.037。
  • 所有归一化方法下各候选参考组织的SUV测量均显示良好可重复性(ICC > 0.7)。
  • 肝和血池对SUVmean与SULmean-James的离散度最低(CQV 9.4%–16.8%),为最稳定的参考组织。
  • 脾摄取个体间变异较大(CQV 19.9%–22.2%),不适合作为常规参考组织。

临床怎么用

  • 定量分析[68Ga]Ga-Pentixafor PET/CT时,可优先采用SUL-James归一化并以肝或血池作为参考组织。
  • 避免将脾作为常规参考组织,因其个体间变异较大。

局限性

  • 研究为回顾性设计,样本为40例无恶性肿瘤患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: [68Ga]Ga-Pentixafor PET/CT enables visualization of C-X-C chemokine receptor 4 expression, but quantitative accuracy depends on standardized uptake value (SUV) normalization and reference tissue selection. Body composition and variability across candidate organs may confound SUV interpretation.We retrospectively analyzed [68Ga]Ga-Pentixafor PET/CT scans from 40 patients without malignancy. Regions of interest were placed in the blood pool, liver, spleen, bone marrow, and muscle. Three SUV were calculated: SUV normalized by body weight (SUVbw) and SUV normalized by lean body mass (SUL), the latter derived using two methods—the conventional James formula and the Janmahasatian (Janma) formula, a revised method optimized for obese individuals. Correlations with body weight were quantified using Spearman correlation coefficients and the slope-to-intercept ratio (a/b) from linear regression analyses, while interobserver reproducibility and variability were evaluated using the intraclass correlation coefficient (ICC) and the coefficient of quartile variation (CQV), respectively. This study aimed to identify an optimal normalization strategy and reliable reference tissue for quantitative [68Ga]Ga-Pentixafor PET/CT. RESULTS: SUVmean, SULmean-James, and SULmean-Janma exhibited significant body-weight dependence in all candidate tissues except muscle, with the strongest association observed in the liver (right liver lobe: ρ = 0.635, 0.576, and 0.650, respectively). Compared with SUVbw, SUL derived from the James formula effectively reduced body-weight-related fluctuations in SUV measurements: a/b decreased from 0.065 to 0.034 in the right liver lobe, 0.036 to 0.021 in the left liver lobe, and 0.076 to 0.037 in the spleen. Across all normalization methods, SUV measurements demonstrated good repeatability in all candidate reference tissues (ICC > 0.7). Variability analysis showed that the liver and blood pool yielded the lowest dispersion for both SUVmean and SULmean-James (CQV: 9.4%-16.8%), identifying them as the most stable reference tissues. In contrast, splenic uptake exhibited substantial inter-individual variability (CQV: 19.9%-22.2%), suggesting it is unsuitable as a routine reference tissue. CONCLUSION: SUL-James normalization, together with the liver or blood pool as reference tissues, provides robust and reproducible quantification for [68Ga]Ga-Pentixafor PET/CT. These findings support standardized imaging frameworks and may facilitate treatment response evaluation, prognostic assessment, and harmonization across centers.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Liu Y, Tang R, Yang H, et al. Selection of SUV normalization and reference tissue for quantitative [68Ga]Ga-Pentixafor PET/CT analysis. EJNMMI Res. 2026. PMID: 41486224. doi:10.1186/s13550-025-01370-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。